Details
Stereochemistry | RACEMIC |
Molecular Formula | C28H30FN3OS.C4H4O4 |
Molecular Weight | 591.693 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.FC1=CC=C(C=C1)N2CCN(CCCC(=O)NC3C4=C(CSC5=C3C=CC=C5)C=CC=C4)CC2
InChI
InChIKey=ZDZXCYHMVFLGMT-BTJKTKAUSA-N
InChI=1S/C28H30FN3OS.C4H4O4/c29-22-11-13-23(14-12-22)32-18-16-31(17-19-32)15-5-10-27(33)30-28-24-7-2-1-6-21(24)20-34-26-9-4-3-8-25(26)28;5-3(6)1-2-4(7)8/h1-4,6-9,11-14,28H,5,10,15-20H2,(H,30,33);1-2H,(H,5,6)(H,7,8)/b;2-1-
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | C28H30FN3OS |
Molecular Weight | 475.621 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/7826563Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/7496051
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7826563
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/7496051
Monatepil is a calcium antagonist that, as do existing calcium antagonists, inhibits the influx of extracellular Ca 2 + through voltage-dependent Ca 2 + channels. It is a new type of antihypertensive agent. Its unique chemical structure was specially designed with intrinsic calcium antagonist and a1 -adrenoceptor-blocking moieties, creating a dual mechanism of action. Positive effects on plasma lipid metabolism are derived from the a1 -adrenoceptor-blocking activity and the antiatherosclerotic effect derives from the calcium antagonist properties. The novel structure of monatepil produces a slow onset of action and a long-lasting antihypertensive effect in experimental animals.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Acyl-CoA:cholesterol acyltransferase (Macaca fuscata) Sources: http://www.ncbi.nlm.nih.gov/pubmed/9234833 |
|||
Target ID: GO:0014824 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7509897 |
20.8 nM [IC50] | ||
Target ID: GO:0070509 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2002473 |
16.0 nM [IC50] | ||
Target ID: CHEMBL2094251 Sources: http://adisinsight.springer.com/drugs/800001558 |
|||
Target ID: Lipid hydroperoxidation of low density lipoprotein Sources: http://www.ncbi.nlm.nih.gov/pubmed/8740082 |
28.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7826564
Treatment of essential hypertension:
The initial dose of monatepil was 30 mg/day in monotherapy and 15 mg/day in combination therapy; the daily dose was titrated to 60 mg/day according to the antihypertensive response.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9512869
Treatment of human skin fibroblasts with 2 x 10(-5) M of monatepil for 6 hours resulted in an increase in LDL receptor mRNA to 163% of the control level
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:49:14 GMT 2023
by
admin
on
Sat Dec 16 05:49:14 GMT 2023
|
Record UNII |
W456I35SKD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C81688
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
PRIMARY | |||
|
103379-03-9
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
PRIMARY | |||
|
185537-12-6
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
SUPERSEDED | |||
|
m832
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL172853
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
PRIMARY | |||
|
HH-8
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
PRIMARY | |||
|
5282401
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
PRIMARY | |||
|
132046-06-1
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
SUPERSEDED | |||
|
W456I35SKD
Created by
admin on Sat Dec 16 05:49:14 GMT 2023 , Edited by admin on Sat Dec 16 05:49:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|